Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*)

What Was Tested

The paper reports a study of Liraglutide in the context of low blood pressure and orthostatic hypotension, published as a randomized controlled trial.

Who Took Part

The study group was 929 subjects.

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

One subject withdrew immediately after randomization and before exposure.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

Neither the subjects nor the staff measuring them knew who was on Liraglutide, so expectations could not easily colour the readings.

A 16-week, randomized, double-blind, double-dummy, four-arm, active control trial was carried out.

What Was Measured

Topics PubMed links to this paper include Asian People, Blood Pressure, China, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Hypoglycemic Agents and India.

What This Means in Plain Language

The paper is a randomized and double-blind study of Liraglutide in 929 subjects in people with low blood pressure and orthostatic hypotension.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 12 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Liraglutide compound page, Low blood pressure and orthostatic hypotension research.